JPS58113756A - Production of artificial carrier - Google Patents

Production of artificial carrier

Info

Publication number
JPS58113756A
JPS58113756A JP20987081A JP20987081A JPS58113756A JP S58113756 A JPS58113756 A JP S58113756A JP 20987081 A JP20987081 A JP 20987081A JP 20987081 A JP20987081 A JP 20987081A JP S58113756 A JPS58113756 A JP S58113756A
Authority
JP
Japan
Prior art keywords
soln
carrier
particles
gelatin
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP20987081A
Other languages
Japanese (ja)
Other versions
JPS6332149B2 (en
Inventor
Mikio Ikeda
池田 幹雄
Takayuki Tomizawa
富沢 孝之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Inc
Original Assignee
Fujirebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Inc filed Critical Fujirebio Inc
Priority to JP20987081A priority Critical patent/JPS58113756A/en
Priority to EP19820301235 priority patent/EP0062968B2/en
Publication of JPS58113756A publication Critical patent/JPS58113756A/en
Publication of JPS6332149B2 publication Critical patent/JPS6332149B2/ja
Granted legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/548Carbohydrates, e.g. dextran
    • GPHYSICS
    • G03PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03CPHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
    • G03C1/00Photosensitive materials
    • G03C1/005Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein
    • G03C1/04Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein with macromolecular additives; with layer-forming substances
    • G03C1/047Proteins, e.g. gelatine derivatives; Hydrolysis or extraction products of proteins
    • G03C2001/0471Isoelectric point of gelatine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

PURPOSE:To obtain a carrier for serodiagnosis, etc. which can be preserved for a long period of time and has excellent characteristics by contg. anionic or nonionic surfactants in an aq. soln. of gelatin, water soluble polysaccharides and sodium polymetaphosphate prior to controlling of said soln. to a specific pH range. CONSTITUTION:An aq. soln. of gelatin, water soluble polysaccharides such as gum arabic and sodium polymetaphosphosphate (in other words, only water is used, without making combination use of org. solvents) is maintained at temp. higher than the gelling temp. of the gelatin and a soln. of anionic or nonionic surfactants are added thereto; thereafter a soln. of acetic acid, etc. is dropped to the soln. under stirring to adjust 2.5-6.0pH and to form particles. According to the conditions such as pH and compsns. of raw materials, grain sizes can be controlled to desired values. After the formation of the particles, the soln. is cooled and when the temp. drops to <=10 deg.C, aldehyde crosslinking agents are added to the soln. to insolubilize the same. The particles are centrifugally sepa rated and washed, whereby the carrier is obtained. This carrier is obtainable in good yields and with uniform properties, and is preservable for a long period of time. The carrier bound with antigens or antibodies is stable without liberation of the antigens, etc. even when preserved by freeze drying.

Description

【発明の詳細な説明】 定などに広く利用しうる−新規な人工ヘ担体の生産方法
の改良に関する。抗原、抗体反応を利用する臨床検査等
の分野において、抗原または抗体をある適当な大きさの
粒子を担体としてそれに吸着もしくは結合させ、それぞ
れに対応する抗体または抗原の存在によってこの感作さ
れた担体の凝集を起させる方法は間接受身凝集反応と呼
ばれている。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an improvement in a method for producing a novel artificial carrier, which can be widely used in various applications. In fields such as clinical tests that utilize antigen and antibody reactions, antigens or antibodies are adsorbed or bonded to particles of an appropriate size as carriers, and the carriers are sensitized by the presence of the corresponding antibodies or antigens. The method of causing aggregation is called indirect passive agglutination reaction.

そして、この間接受身凝集反応は被検液中の抗体や抗原
を高感度に検出できるので、いろいろの疾患の血清学的
診断に広く用いられている。
Since this indirect passive agglutination reaction can detect antibodies and antigens in a sample liquid with high sensitivity, it is widely used for serological diagnosis of various diseases.

この反応に用いられる担体としては、ポリスチレンラテ
ックス、カオリン、炭末などの非生物学的粒子と、動物
赤血球、細菌菌体のような生物学的粒子とがある。一般
に非生物学的粒体の担体は、化学的に安定で、それ自身
抗原活性を有しないなどの利点はあるが、抗原あるいは
抗体が密に吸着されにくいという欠点がある。たとえば
、保存のために凍結乾燥すると抗原や抗体が担体から遊
離してしまうのである。そのために、やむなく液体中で
冷暗所に保存するという手段がとられているが、その結
果長期間保存することができない。また、非生物学的担
体のうち、炭末とカオリンは一定の大きさの粒子を選出
することが困難であり、ポリスチレンラテックスは反応
の媒質として望ましい中性域では非特異凝集である自然
凝集をおこす危険がある= 一方、生物学的担体である動物赤血球や細菌菌体はそれ
ぞれの大きさが一定であるという利点はあるものの、生
物の種類によって粒子の大きさは定まっており、目的に
応じた任意の大きさの粒子を得ることはできない。たと
えば、動物赤血球は大きさの一定した最も入手しゃすい
担体であるが血球表面に固有の抗原を有しておシ、抗体
との間で非特異凝集反応である交差反応を起こして目的
とする凝集反応に誤まりを与える可能性がある。
Carriers used in this reaction include non-biological particles such as polystyrene latex, kaolin, and charcoal powder, and biological particles such as animal red blood cells and bacterial cells. In general, non-biological particulate carriers have advantages such as being chemically stable and having no antigenic activity themselves, but have the disadvantage that antigens or antibodies are difficult to adsorb closely. For example, when freeze-drying for storage, antigens and antibodies are released from the carrier. For this reason, it is unavoidable to store it in a liquid in a cool, dark place, but as a result, it cannot be stored for a long period of time. Furthermore, among non-biological carriers, it is difficult to select particles of a certain size for charcoal powder and kaolin, and polystyrene latex exhibits spontaneous aggregation, which is non-specific aggregation, in the neutral region, which is desirable as a reaction medium. On the other hand, although animal red blood cells and bacterial cells, which are biological carriers, have the advantage of having a fixed size, the particle size is fixed depending on the type of organism, and it depends on the purpose. It is not possible to obtain particles of arbitrary size. For example, animal red blood cells are the most readily available carrier with a constant size, but they have unique antigens on the surface of the blood cells, which cause a cross-reaction, a non-specific agglutination reaction, with antibodies. This may cause errors in the agglutination reaction.

さらに、赤血球の生物学的、化学的および物理的特性値
が動物の個体間でばらついてしまって常に一定品質の血
球を入手することが難しいという欠点がある。
Another disadvantage is that the biological, chemical, and physical properties of red blood cells vary among individual animals, making it difficult to obtain blood cells of constant quality.

本発明者らはこれらの欠点のないすぐれた担体を開発す
べく種々検討の結果、ゼラチン、水溶性多糖類、および
ポリメタリンi4..ナトリウムを含み、水とアルコー
ル等の混合物を溶媒とする溶液を攪拌下で一調整するこ
とに工っで粒子を析出させ、この粒子をアルデヒド系架
橋剤で処理して不溶化すれば、従来の欠点を尽く解消し
たすぐれた担体が得られることを見出し、この内容を既
に特許出4願した。そして、その後アルコール等の親水
性有機溶媒を用いなくとも人工坦体が好収率で得られる
ことを見出してこの内容も特許出願した。しかしながら
、いずれの方法においても生成した粒子の凝集を防止す
るために一調整後に界面活性剤を添加していた。本発明
は、溶媒が水のみで親水性有機溶媒を用いない方法にお
いて、界面活性剤を一調整前に予め添加しておけは担体
の収量が増加することに基いてなされたものである。
The present inventors conducted various studies to develop excellent carriers free from these drawbacks, and as a result, gelatin, water-soluble polysaccharides, and polymethalin i4. .. If particles are precipitated by adjusting a solution containing sodium and using a mixture of water, alcohol, etc. as a solvent under stirring, and the particles are insolubilized by treatment with an aldehyde-based crosslinking agent, the drawbacks of the conventional method can be overcome. We have discovered that an excellent carrier that completely eliminates these problems can be obtained, and have already filed four patent applications on this subject. Later, they discovered that an artificial carrier could be obtained in good yield without using a hydrophilic organic solvent such as alcohol, and filed a patent application for this content as well. However, in both methods, a surfactant was added after the initial adjustment to prevent agglomeration of the generated particles. The present invention was made based on the fact that in a method in which the solvent is only water and no hydrophilic organic solvent is used, the yield of the carrier increases if a surfactant is added in advance before any adjustment.

すなわち本発明は、ゼラチン、水溶性多糖類、およびポ
リメタリン酸ナトリウムを含み、温度がゼラチンのグル
化温度以上である水溶液を、攪拌しつつ酸を加えてpH
2,5〜6.0に調整し、その後アルデヒド系架橋剤を
作用せしめて不溶化する人工担体の生産方法において、
前記の一調整を行なうまえに陰イオン系または非イオン
系の界面活性剤を前記水溶液に含有させて幹くこと1に
%徴とする人工担体の生産方法に関するものである。
That is, in the present invention, an aqueous solution containing gelatin, a water-soluble polysaccharide, and sodium polymetaphosphate and having a temperature equal to or higher than the gluing temperature of gelatin is adjusted to pH by adding acid while stirring.
2.5 to 6.0, and then treated with an aldehyde crosslinking agent to make it insolubilized.
The present invention relates to a method for producing an artificial carrier by adding an anionic or nonionic surfactant to the aqueous solution prior to the above adjustment.

本発明に使用するゼラチンは通常は市販品をそのまま用
いればよい。市販品のなかでは液性ゼラチンが好ましい
As the gelatin used in the present invention, commercially available gelatin may generally be used as is. Among commercially available products, liquid gelatin is preferred.

水溶性多糖類は増粘剤または糊料として使用しうるもの
であり、多糖類の誘導体および塩も含まれる。例として
は、アラビアゴム、カルボキシメチルセルロース、アル
ギン酸ナトリウム、寒天、カラグーナンなどを挙げるこ
とができるが、特にアラビアゴムが好適である。
Water-soluble polysaccharides can be used as thickeners or thickeners, and also include derivatives and salts of polysaccharides. Examples include gum arabic, carboxymethyl cellulose, sodium alginate, agar, carrageenan, etc., with gum arabic being particularly preferred.

ポリメタリン酸ナトリウムは化学式(NaPO3)nで
表わされる物質であシ、たとえば四メタリン酸ナトリウ
ム、ヘキサメタリン酸ナトーリウムの如きものである。
Sodium polymetaphosphate is a substance represented by the chemical formula (NaPO3)n, such as sodium tetrametaphosphate and sodium hexametaphosphate.

そのほかのものとしては、担体を着色する場合には、着
色剤を粒子形成前に溶液・に加えておくのがよい。着色
を必要とする例としては、本発明品を間接受身凝集反応
の担体として用いる場合を挙げることができる。すなわ
ち、本発明品は通常は無色不透明であるところから、こ
れを着色するととによって凝集像の判定を容易にするこ
とができる。着色剤としては、たとえば食用赤色3号、
ローダミン、ローズベンガル、ポンノー3R,yNルゝ
−81フクシン、エオシン、およびニュートラルレッド
などの赤色色素、あるいはクリスタル/々イオレット、
トルイジンブルーおよびメチ。レンブルーなどの青色色
素等を用いうる。しかしながら、1ノアクチイブ・レッ
ド、ダイレクト・ブルーなどの反応性染料で着色すれば
色落ちしないことから、反応性染料が特に好適である。
Alternatively, if the carrier is to be colored, a coloring agent may be added to the solution prior to particle formation. An example where coloring is required is when the product of the present invention is used as a carrier for an indirect passive aggregation reaction. That is, since the product of the present invention is normally colorless and opaque, by coloring it, the agglomerated image can be easily determined. As a coloring agent, for example, Food Red No. 3,
Red pigments such as rhodamine, rose bengal, Pontno 3R, yN Ru-81 fuchsin, eosin, and neutral red, or crystal/metal iolet,
toluidine blue and methi. A blue dye such as Renblue can be used. However, reactive dyes such as Active Red and Direct Blue do not cause color fading, so reactive dyes are particularly preferred.

着色剤以外にも目的に応じ種々の物質を添加してもよい
ことはいうまでもない。
It goes without saying that in addition to the coloring agent, various substances may be added depending on the purpose.

一調整前の溶液におけるこれら各物質の濃度としては、
ゼラチン0.01〜2−程度、好ましくは005〜1.
0%程度、そして水溶性多糖類0.01〜2チ程度、好
ましくは0.05〜1.0−程度である。ポリメタリン
酸ナトリウムはゼラチン乾燥重量の3〜15チ程度を含
有させる゛ようにするのがよい。各物質はこれらの濃度
範囲において、所望の粒子の粒径および物性に応じて適
宜定めればよい。着色剤を添加する場合には、通常は0
.005〜0.5es程度であるが、反応性染料を用い
ればゼラテン乾燥重量の1〜5チ程度で足りる。
The concentration of each of these substances in the solution before adjustment is as follows:
Gelatin is about 0.01 to 2, preferably 005 to 1.
The content of the water-soluble polysaccharide is about 0.01 to 2%, preferably about 0.05 to 1.0%. It is preferable that sodium polymetaphosphate is contained in an amount of about 3 to 15 times the dry weight of gelatin. Each substance may be appropriately determined within these concentration ranges depending on the particle size and physical properties of the desired particles. When adding colorants, usually 0
.. 0.005 to 0.5 es, but if a reactive dye is used, about 1 to 5 es of gelaten dry weight is sufficient.

本発明においては、このような溶液に声調豊前にさらに
陰イオン系または非イオン系の界面活性剤を含・有させ
るところに特徴がある。
The present invention is characterized in that such a solution further contains an anionic or nonionic surfactant.

陰イオン系界面活性剤の例としては、アルキルスルホコ
ハク酸、アルキルスルホマレイン酸、アルキル硫酸エス
テル、ポリオキシエチレンアルキルエーテル硫酸エステ
ルなど、そして非イオン系界面活性剤の例としては、ポ
リオキシエチレン脂肪酸エステル、ポリオキシエチレン
アルキルエーテル、ポリオキシエチレンアルキルフェニ
ルエーテル、ポリエチレングリコール脂肪酸エステルな
どを挙げることができる。界面活性剤は粒子の凝集を防
止する目的で添加するのであるが、陽イオン系の界面活
性剤では粒子の凝集を防止することができないので本発
明の対象外である。声調豊前の溶液における濃度として
は、陰イオン系界面活性剤の場合は0.001〜0.0
1%程度、非イオン系界面活性剤の場合は0.01〜0
1チ程度で凝集防止効果が得られる。溶液を冷却すれば
もっと低このような溶液を調製する過程は問うところで
はなく、例えば各々を温水に溶解してから混合してもよ
く、各々を一緒に溶解してもよい。しかしながら、水溶
性多糖類には不溶成分も少量台まれていることが多いと
ころから、別途に溶解して添加するのがよい。一方、ゼ
ラチンは等電点以下の声では水溶性多糖類と反応して白
濁を生ずるので酸性ゼラチンを用いる場合にはアルカリ
を加えて溶液のPHを少なくともその付近にまで高めて
おくのがよい。しかしながら、この白濁は生じた後でも
アルカリを添加することによって消すことができる。い
ずれにせよ、溶液は酸の添加を開始するまえには白濁の
ない状態にしておかなければならない。
Examples of anionic surfactants include alkyl sulfosuccinic acids, alkyl sulfomaleic acids, alkyl sulfates, polyoxyethylene alkyl ether sulfates, and examples of nonionic surfactants include polyoxyethylene fatty acid esters. , polyoxyethylene alkyl ether, polyoxyethylene alkyl phenyl ether, polyethylene glycol fatty acid ester, and the like. Surfactants are added for the purpose of preventing particle aggregation, but cationic surfactants cannot prevent particle aggregation and are therefore outside the scope of the present invention. In the case of anionic surfactants, the concentration in the solution of tone Buzen is 0.001 to 0.0.
Approximately 1%, 0.01 to 0 for nonionic surfactants
Agglomeration prevention effect can be obtained with about 1 inch. The process for preparing such solutions is not critical; for example, each may be dissolved in hot water and then mixed, or each may be dissolved together. However, since water-soluble polysaccharides often contain small amounts of insoluble components, it is preferable to dissolve them separately and add them. On the other hand, when gelatin is below its isoelectric point, it reacts with water-soluble polysaccharides and becomes cloudy, so when using acidic gelatin, it is advisable to add an alkali to raise the pH of the solution to at least around that point. However, even after this cloudiness occurs, it can be eliminated by adding an alkali. In any case, the solution must be free from cloudiness before starting the addition of acid.

溶液の温度はゼラチンのグル化温度以上でなければなら
ない。この温度はゼラチンの濃度等によって異なるが通
例25〜30℃程度である。良好な粒子形成の観点から
特に35〜50℃程度がよい。
The temperature of the solution must be above the gluing temperature of gelatin. This temperature varies depending on the concentration of gelatin, etc., but is usually about 25 to 30°C. From the viewpoint of good particle formation, the temperature is particularly preferably about 35 to 50°C.

次に、この溶液を攪拌しながら酸を加えて−2,5〜6
0に調整する。この工程は粒子を生成させるところであ
る。均一な粒子を形成させるために、35〜50℃に加
温を続け、適度に攪拌しながら酸を滴下していくのがよ
い。pH2,5〜60の範囲における至適の−は原料溶
液の組成および目的とする粒径によって異なるので予め
実験を行なって定めるのがよい。たとえば得られた粒子
を抗原感作用担体に用いる場合には2〜10μ程度の粒
径にするのがよく、その場合至適の−は40〜5.5の
範囲にある。この−調整に使用する酸は特に限定される
ものではなく無機酸でも有機酸でもよいが、なるべくお
だやかなものがよく、たとえば酢酸などが好適である。
Next, add acid to this solution while stirring and add -2,5 to 6
Adjust to 0. This step is where particles are generated. In order to form uniform particles, it is preferable to continue heating at 35 to 50°C and drop the acid while stirring moderately. The optimum pH in the range of 2.5 to 60 varies depending on the composition of the raw material solution and the intended particle size, so it is best to determine it by conducting experiments in advance. For example, when the obtained particles are used as an antigen-sensitizing carrier, the particle size is preferably about 2 to 10 μm, and in this case, the optimum value of - is in the range of 40 to 5.5. The acid used for this adjustment is not particularly limited and may be either an inorganic acid or an organic acid, but preferably one that is as mild as possible, such as acetic acid.

本工程で生成した粒子は系の温度をゼラチンのグル化温
度以下に下けても消失しないので母液との平衡関係はな
い。また、ゼラチンと水溶性多糖類との混合比にもよる
が、粒子はほとんどの場合正に帯電しておシ、その表面
にはポリメタリン酸イオンが配向していていわゆる電気
二重層を形成している。そして、このことが粒子の安定
な分散を促しているのである。
The particles produced in this step do not disappear even when the temperature of the system is lowered below the gluing temperature of gelatin, so there is no equilibrium relationship with the mother liquor. Also, although it depends on the mixing ratio of gelatin and water-soluble polysaccharide, in most cases the particles are positively charged, and polymetaphosphate ions are oriented on the surface, forming a so-called electric double layer. There is. This also promotes stable dispersion of particles.

酸の添加後は生成した粒子の凝集を防止するために速か
に粒子分散液を冷却するのがよい。そして、液温が10
℃以下になったところでアルデヒド系架橋剤を添加して
粒子を不溶化する。この架橋剤の添加量はゼラチン乾燥
重量の0.1〜200チ程度であシ、添加後は一夜程度
放置して架橋反応を充分に行なわせる。架橋剤の例とし
ては、グルタルアルデヒド、ホルムアルデヒド、グリオ
キザール、クロトンアルデヒド、アクロレイン、アセト
アルデヒドなどを挙げることができるが、特にグルタル
アルデヒドが好適である。
After adding the acid, it is preferable to quickly cool the particle dispersion to prevent the formed particles from agglomerating. And the liquid temperature is 10
When the temperature drops below 0.degree. C., an aldehyde crosslinking agent is added to insolubilize the particles. The amount of this crosslinking agent added is about 0.1 to 200 g of the dry weight of gelatin, and after addition, the mixture is left to stand for about one night to allow the crosslinking reaction to occur sufficiently. Examples of the crosslinking agent include glutaraldehyde, formaldehyde, glyoxal, crotonaldehyde, acrolein, and acetaldehyde, with glutaraldehyde being particularly preferred.

アルデヒド系架橋剤で処理後は粒子を遠心分離等で回収
して、必要によシ洗浄する。洗浄は粒子分散のために用
いた界面活性剤と同じものを同濃度で含む水で2〜3回
行なえばよい。
After treatment with an aldehyde-based crosslinking agent, the particles are collected by centrifugation or the like and washed if necessary. Washing may be carried out two or three times with water containing the same surfactant at the same concentration as that used for particle dispersion.

このようにして得られた担体を種々の用途に供すればよ
いが、架橋が不充分な場合には塩類溶液中で膨潤するこ
とがある。そこでこのような用途に用いる場合にはアル
デヒド系架橋剤で処理1て膨潤を防止するのがよい。例
えば、抗原を感作する場合にはリン酸緩衝液中で行なう
ので、赤血球を固定化する条件でホルマリン処理する。
The carrier thus obtained may be used for various purposes, but if crosslinking is insufficient, it may swell in a salt solution. Therefore, when used for such purposes, it is recommended to treat with an aldehyde crosslinking agent to prevent swelling. For example, when sensitizing an antigen, it is carried out in a phosphate buffer, so formalin treatment is performed under conditions that fix red blood cells.

この処理によって膨潤を防止するとともにホルマリンの
殺菌効果によって長期間の保存に耐える担体が得られる
This treatment prevents swelling and provides a carrier that can withstand long-term storage due to the sterilizing effect of formalin.

本発明の担体は抗原、抗体、酵素などを巾広く固定する
ことができる。たとえば、抗原とか抗体を感作する場合
には動物赤血球を担体として行なう常法に準じて行えば
よい。
The carrier of the present invention can immobilize a wide variety of antigens, antibodies, enzymes, and the like. For example, when sensitizing an antigen or antibody, a conventional method using animal red blood cells as a carrier may be used.

本発明の担体は間接受身凝集反応の担体として従来最も
すぐれているとされていた動物赤血球と同等の性能を有
し、さらに化学的、物理的に均質かつ安定であり、抗原
活性がなく任意の粒径のものを容易かつ安価に大量生産
できるなど動物赤血球にない、幾多の利点を有するも□
のである。そして本発明は、アルコール等を溶媒に含む
先願発明に対してはこのような有機溶剤を使用しないこ
とによって製造設備を大巾に簡略化しかつ操作を容易に
しておシ、アルコール等を溶媒に用いない先願発明に対
しては界面活性剤の添加時期を変えることによって収率
を向上させている。
The carrier of the present invention has performance equivalent to that of animal red blood cells, which was conventionally considered to be the best carrier for indirect passive agglutination reactions, and is chemically and physically homogeneous and stable, has no antigenic activity, and has no antigenic activity. It has many advantages over animal red blood cells, such as the ability to easily and inexpensively mass-produce particle-sized red blood cells.
It is. In addition, the present invention greatly simplifies the manufacturing equipment and facilitates operation by not using such organic solvents in contrast to the prior invention that contains alcohol or the like as a solvent. For the prior invention in which the surfactant is not used, the yield is improved by changing the timing of adding the surfactant.

以下、実施例及び担体の使用例を示す。なお、本明細書
において特に記載がなければチは重量%を表わしている
Examples and usage examples of carriers are shown below. In this specification, unless otherwise specified, q represents weight %.

実施例1 等電点がpH9であるゼラチン4F’i40℃の温水に
溶解して100 atとし、10チの水酸化ナトリウム
溶液でpH9に調整した。アラビアゴム49水に溶解し
て100 mlとし、不溶物tF別した後40℃に加温
した。
Example 1 Gelatin 4F'i having an isoelectric point of pH 9 was dissolved in warm water at 40° C. to a concentration of 100 at, and the pH was adjusted to 9 with a 10-ton sodium hydroxide solution. Gum arabic 49 was dissolved in water to make 100 ml, and after separating insoluble matter tF, it was heated to 40°C.

このようにして得られたゼラチン溶液59m1とアラビ
アゴム溶液501+I11に混合し、この混合液を40
℃の蒸溜水300 tugに加えた。これに10%のへ
キサメタリン酸ナトリウム溶液1.5m/、l容1 i % ホIJオキシエチレンフェニルエーテル(エマ
ルダンA−60、花王石鹸(株)登録商標)溶液8ml
、およびILsダイレクトブルー溶液61を加えた。
Mix 59 ml of the gelatin solution obtained in this way with 501 ml of gum arabic solution + 11 ml of gum arabic solution, and add 40 ml of this mixed solution.
Added to 300 tug of distilled water at °C. Add to this 1.5 m of 10% sodium hexametaphosphate solution, 8 ml of 1 i% HoIJ oxyethylene phenyl ether (Emuldan A-60, registered trademark of Kao Soap Co., Ltd.) solution.
, and ILs Direct Blue Solution 61 were added.

盗いで、この溶液を40℃に保ち、攪拌しなから10容
蓋チ酢酸溶液を滴下して…48に調整し、粒子を生成さ
せた。
The solution was kept at 40° C., and while stirring, 10 volumes of thiacetic acid solution were added dropwise to adjust the temperature to 48° C., and particles were generated.

粒子分散液を氷冷して5℃にしてからゲルタールアルデ
ヒド1.31を加え、′よ〈攪拌後との温度で一夜装置
した。それからこの粒子分散液を2 ooo rpmで
10分間遠心分離して粒子をベレットとして回収した。
The particle dispersion was ice-cooled to 5°C, 1.31 g of gel tar aldehyde was added, and the mixture was kept overnight at the same temperature as after stirring. The particle dispersion was then centrifuged at 2 ooo rpm for 10 minutes to collect the particles as pellets.

この粒子を0.02容量−のエマルダンA−60溶液に
懸濁して遠心分離する洗浄操作を3回繰返してから粒子
濃度が5チになるように4容i%ホルマリン溶液に分散
し、5℃で1週間静置した。
The particles were suspended in 0.02 volume of Emuldan A-60 solution and centrifuged. The washing operation was repeated three times, and then dispersed in 4 volume i% formalin solution so that the particle concentration was 5 °C. It was left undisturbed for one week.

本例で得られた担体粒子は6.2IIであり、その75
チは3〜6μの範囲にあった。
The carrier particles obtained in this example were 6.2II, and the 75
The thickness was in the range of 3-6μ.

実施例2 1容量チのエマルダンA−60溶液8mlのかわすKI
 %アルキルスルホマレイン酸(チモールEp1花王石
鹸(抹)登録商標)溶液2mlを用い、そして1チダイ
レクトプルー溶液6 mlのかわシに1%リアクティブ
レッド6 ml f用いたほかは実施例1と同様にして
担体粒子を調製した。但し、酢酸を滴下して調整した…
は46であった。こうして得られた担体粒子pH11で
あシ、その75チは3〜6μの範囲にあった。
Example 2 Dodge KI of 8 ml of emaldan A-60 solution of 1 volume
Same as Example 1 except that 2 ml of % alkyl sulfomaleic acid (Thymol Ep1 Kao Soap (registered trademark)) solution was used, and 6 ml of 1% Reactive Red was used for 6 ml of 1% direct pull solution. Carrier particles were prepared as follows. However, it was adjusted by dropping acetic acid...
was 46. The carrier particles thus obtained had a pH of 11 and a particle size of 75 μm in the range of 3 to 6μ.

実施例3 下記の点を除いて実施例1と同様にして担体粒子を調製
した。
Example 3 Carrier particles were prepared in the same manner as in Example 1 except for the following points.

すなわち、まずアラビアゴム4IIのかわシにカルブキ
シメチルセルロース111i、そしてl容量チのエマル
ダンA−60溶液8mlのかわシに1%デモールEp溶
液Q、5 mlを用いた。それから、添加量についても
、ゼラチン、10チヘキサメタリン酸ナトリウム溶液、
1%ダイレクトブルー溶液、およびグルタルアルデヒド
をいずれも4分の1にした。また、−も4.8から4.
6にした。このようにして得られた担体粒子は4.81
であシ、その95チが08〜1.5μの範囲にあった。
That is, first, carboxymethylcellulose 111i was used in a wafer of gum arabic 4II, and 5 ml of a 1% Demol Ep solution Q was used in 8 ml of a 1-volume emuldan A-60 solution. Then, regarding the amount of addition, gelatin, 10 thihexametaphosphate sodium solution,
Both the 1% Direct Blue solution and glutaraldehyde were reduced to one quarter. Also, - is also 4.8 to 4.
I made it 6. The carrier particles thus obtained were 4.81
Yes, that 95 inch was in the range of 08 to 1.5μ.

実施例4 下記の点を除いて実施例1と同様にして担体粒子を調製
した。
Example 4 Carrier particles were prepared in the same manner as in Example 1 except for the following points.

すなわち、ゼラチン溶液’r: 50 mlから40t
nlにし、アラビアゴム溶液を5Qmlから60rrr
lに変えた。それから、10チヘキサメタリン酸ナトリ
ウム溶液1に1.6 mlから1.21nlに、1容量
チェマルグ7A−60溶液8rugを1チデモ一ルEp
溶液2Mに、1%ダイレクトブルー6 ml f 4.
8 mlに、そしてグルタルアルデヒド’i 1.3 
#から1.Ogにそれぞれ変えた。また、酢酸の滴下終
了pHf:4.2とした。
That is, gelatin solution'r: 50 ml to 40t
nl and add gum arabic solution from 5Qml to 60rrr.
Changed to l. Then, from 1.6 ml to 1.21 nl in 10 thiexametaphosphate solution, 1 volume of Chemarg 7A-60 solution 8 rug was added to 1 tidemole Ep.
6 ml of 1% Direct Blue in a 2M solution 4.
8 ml and glutaraldehyde'i 1.3
# to 1. I changed each to Og. Further, the pH at the end of the dropwise addition of acetic acid was set to 4.2.

このようにして得られた担体粒子は9.6gであり、そ
の90%が1〜2μの範囲にあった。
The carrier particles thus obtained weighed 9.6 g, 90% of which were in the 1-2 micron range.

実施例5 下記の点を除いて実施例1と同様にして担体粒子を調製
した。
Example 5 Carrier particles were prepared in the same manner as in Example 1 except for the following points.

すなわち、ゼラチン溶液t 50 mlから60m1に
し、アラビアゴム溶液を50m1から40 mlに変え
た。それから、10%へキサメタリン酸ナトリウム溶液
k 1.6 mlから2 mlに、1容量チェマルrン
A−60溶液ii%デモールEp溶液2mlに、1チダ
イレクトブルー6 #It f 7.2 mlに、そし
てグルタルアルデヒドを1,3gから1.81Iにそれ
ぞれ変えた。また、酢酸の滴下終了p)lを4.6とし
た。
That is, the gelatin solution was changed from 50 ml to 60 ml, and the gum arabic solution was changed from 50 ml to 40 ml. Then, from 1.6 ml to 2 ml of 10% sodium hexametaphosphate solution, 1 volume of Chemarun A-60 solution ii 2 ml of % Demol Ep solution, 1 ml of TiDirect Blue 6 #It f to 7.2 ml, Then, the amount of glutaraldehyde was changed from 1.3g to 1.81I. Further, the end p)l of acetic acid dropwise addition was set to 4.6.

このようにして得られた担体粒子は10.4.9であシ
、その75%が3〜6μの範囲であった。
The carrier particles thus obtained had a particle diameter of 10.4.9, 75% of which were in the range of 3-6μ.

使用例1 実施例1で得られた担体粒子を濃度が5チになるように
pH7,2のリン酸塩緩衝生理食塩水(以下PBSと略
記する。)に分散し、その20m1を5ppmのタンニ
ン酸を含むpH7,2のPH820mlと混合した。
Usage Example 1 The carrier particles obtained in Example 1 were dispersed in phosphate buffered saline (hereinafter abbreviated as PBS) with a pH of 7.2 to a concentration of 5 ppm, and 20 ml of the suspension was mixed with 5 ppm of tannin. It was mixed with 820 ml of pH 7.2 containing acid.

混合液を37℃で15分間加温後遠心分離して、生理食
塩水で充分洗浄してから5%になるようにPH6,4の
PBSに分散し全量を20mA!とじた。一方、pH6
,4の、 PBS中に浮遊させた梅毒病原体トレポネー
マ・・母す−ダムを超音波処理して破壊し、抗原液とし
た。
The mixture was heated at 37°C for 15 minutes, centrifuged, thoroughly washed with physiological saline, and then dispersed in PBS with a pH of 6.4 to a concentration of 5%, and the total volume was 20mA! Closed. On the other hand, pH6
, 4, the syphilis pathogen Treponema mother dam suspended in PBS was destroyed by ultrasonication and used as an antigen solution.

タンニン酸処理粒子分散液20rrtlと抗原液20r
ulとを混合して37℃で40分間加温した。こうして
得られた抗原感作粒子をpH6,4のPBSで充分に洗
浄し、粒子菖度が5チになるように19m1の分散用メ
ディウムに分散して凍結乾燥した。
Tannic acid treated particle dispersion liquid 20rrtl and antigen solution 20r
ul and heated at 37° C. for 40 minutes. The antigen-sensitized particles thus obtained were thoroughly washed with PBS of pH 6.4, dispersed in 19 ml of dispersion medium so that the particle size was 5 cm, and freeze-dried.

この凍結乾燥品に蒸溜水を加えて凍結乾燥前と同容量に
なるように復元し、梅毒陽性血清についてマイクロタイ
タープレート法で力価を測定した結果を下表に示す。な
お、ヒツジ赤血球を担体とした市販のTPHAキット(
富士臓器製薬(株)製)を用いて同様に測定した結果も
併せて示す。
Distilled water was added to this freeze-dried product to reconstitute it to the same volume as before freeze-drying, and the titer of the syphilis-positive serum was measured using the microtiter plate method. The results are shown in the table below. In addition, a commercially available TPHA kit using sheep red blood cells as a carrier (
The results of a similar measurement using Fuji Organ Pharmaceutical Co., Ltd.) are also shown.

使用例2 実施例1で得られた担体粒子を使用例1と同様にタンニ
ン酸処理した。そして、このタンニン酸処理粒子を粒子
濃度が1%になるようにpH7,2のPH85mlに分
散した。
Use Example 2 The carrier particles obtained in Example 1 were treated with tannic acid in the same manner as in Use Example 1. Then, the tannic acid-treated particles were dispersed in 85 ml of pH 7.2 so that the particle concentration was 1%.

高純度に精製したストレプトキナーゼを3211になる
ようにpH7,2のPH85mlに溶解し、この溶液を
粒子分散液と混合した。
Highly purified streptokinase was dissolved in 85 ml of pH 7.2 to a concentration of 3211, and this solution was mixed with the particle dispersion.

混合液を37℃で30分間加温し、粒子を遠心分離して
生理食塩水で充分に洗浄した。ヱの粒子を濃度が5%に
なるように分散用メディウムに分散し、凍結乾燥して4
℃で保存した。
The mixture was heated at 37° C. for 30 minutes, and the particles were centrifuged and thoroughly washed with saline. Disperse the particles in a dispersion medium to a concentration of 5%, freeze-dry and
Stored at °C.

このようにして得られたストレプトキナーゼ固定化粒子
の力価をマイクロプレート法によって求めたところ下表
に示すような結果が得られる。
When the titer of the streptokinase-immobilized particles thus obtained was determined by the microplate method, the results shown in the table below were obtained.

特許出願人 富士臓器製薬株式会社 代理人弁理士田中政浩Patent applicant: Fuji Organ Pharmaceutical Co., Ltd. Representative Patent Attorney Masahiro Tanaka

Claims (1)

【特許請求の範囲】[Claims] ゼラチン、水、溶性多糖類、およびポリメタリン酸ナト
リウムを含み、温度がゼラチンのダル化温度以上である
水溶液を、攪拌しつつ酸を加えて声2.5〜60に調整
し、その後アルデヒド系架橋剤を作用せしめて不溶化す
る人工担体の生産方法において、前記の一調整を行なう
まえに陰イオン系または非イオン系の界面活性剤を前記
水溶液に含有させておくことを特徴とする人工担体の生
産方法0
An aqueous solution containing gelatin, water, soluble polysaccharides, and sodium polymetaphosphate, whose temperature is above the gelatin dalification temperature, is adjusted to a pH of 2.5 to 60 by adding acid while stirring, and then adding an aldehyde crosslinking agent. A method for producing an artificial carrier in which the aqueous solution is made insolubilized by the action of an anionic or nonionic surfactant prior to the above-mentioned adjustment. 0
JP20987081A 1981-03-18 1981-12-28 Production of artificial carrier Granted JPS58113756A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP20987081A JPS58113756A (en) 1981-12-28 1981-12-28 Production of artificial carrier
EP19820301235 EP0062968B2 (en) 1981-03-18 1982-03-11 Support material for use in serological testing and process for the production thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20987081A JPS58113756A (en) 1981-12-28 1981-12-28 Production of artificial carrier

Publications (2)

Publication Number Publication Date
JPS58113756A true JPS58113756A (en) 1983-07-06
JPS6332149B2 JPS6332149B2 (en) 1988-06-28

Family

ID=16579994

Family Applications (1)

Application Number Title Priority Date Filing Date
JP20987081A Granted JPS58113756A (en) 1981-03-18 1981-12-28 Production of artificial carrier

Country Status (1)

Country Link
JP (1) JPS58113756A (en)

Also Published As

Publication number Publication date
JPS6332149B2 (en) 1988-06-28

Similar Documents

Publication Publication Date Title
US4798786A (en) Living cells encapsulated in crosslinked protein
Gibbons et al. Synthesis of extracellular dextran by cariogenic bacteria and its presence in human dental plaque
US4416813A (en) Artificial carrier for immobilization of biological proteins
US4671954A (en) Microspheres for incorporation of therapeutic substances and methods of preparation thereof
JPH0779694B2 (en) Protection of proteins and similar products
JPS6223826B2 (en)
US4066744A (en) Serological reagent, test slide and method for gonorrheal antibodies
EP0424975B1 (en) Artificial carrier for immobilization of biological proteins and process for production thereof
JPS61207324A (en) Liposome
DE1961541A1 (en) Immunological indicator reagent
Hobson et al. Some studies on the identification of rumen bacteria with fluorescent antibodies
JPH0317103B2 (en)
JPS5951355A (en) Reagent for detecting antiviral antibody
EP0129619B1 (en) Encapsulated cells, their method of preparation and use
JPS58113756A (en) Production of artificial carrier
JPS6332150B2 (en)
Pinheiro et al. Haemorrhagic syndrome of Altamira
JPS6332147B2 (en)
EP0062968B2 (en) Support material for use in serological testing and process for the production thereof
JPS6329223B2 (en)
JPS6332146B2 (en)
JPS6332148B2 (en)
JPS6348021B2 (en)
JPS62209362A (en) Composition for immune agglutination
Evans The effect of hemolytic streptococci and their products on leucocytes

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees
S199 Written request for registration of transfer of right

Free format text: JAPANESE INTERMEDIATE CODE: R313199

Free format text: JAPANESE INTERMEDIATE CODE: R313I99

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370